RxDoctor Payments Data

Diana Gorokhovsky, DO

Family Medicine · Boynton Beach, FLNPI 1982728705

Payments from drug & device makers

$13,831in general payments, 2019–2025

Across 84 payments — averaging $164.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Tosoh Bioscience, Inc.$12K
  • Amgen$995
  • Pfizer$126
  • Novo Nordisk$82
  • AbbVie$43
  • Johnson & Johnson$36
  • plus $113 from 5 others

What the payments were for

  • Food & beverage$1,39510%
  • Gifts$12,43690%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Tosoh Bioscience, Inc.2$12,436
Amgen61$995
Pfizer6$126
Novo Nordisk4$82
AbbVie2$43
Johnson & Johnson(2 entities)2$36
Teva Pharmaceuticals USA, Inc.2$34
Lilly USA, LLC2$31
Amarin Pharma, Inc.1$17
Nalpropion Pharmaceuticals LLC1$16
AstraZeneca1$15

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$13,831 in reported general payments places this provider in the 90th percentile of 7,282 family medicine providers in Florida.

See all family medicine providers in Florida

Medicare billing

Part B allowed, 2024
$1,742,658
Medicare patients
1,502
Services billed
50,972

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide239$250,523
EliquisApixaban107$138,129
XareltoRivaroxaban83$82,644
MounjaroTirzepatide57$59,422
ProliaDenosumab31$54,857
Repatha SyringeEvolocumab23$32,205
JanuviaSitagliptin Phosphate23$27,608
TrulicityDulaglutide25$25,399
JardianceEmpagliflozin19$21,053
SynthroidLevothyroxine Sodium204$18,316
LinzessLinaclotide15$17,092
Bydureon BciseExenatide Microspheres16$12,812
Repatha SureclickEvolocumab20$12,767
Rosuvastatin Calcium763$9,994
Levothyroxine Sodium810$9,170

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$82$250,523239 claims
PfizerEliquis$126$138,129107 claims
Lilly USA, LLCMounjaro, Trulicity$31$84,82182 claims
Johnson & JohnsonXarelto$36$82,64483 claims
AmgenProlia$995$54,85731 claims
AbbVieSynthroid, Linzess$43$35,408219 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 7,282 family medicine providers in Florida.

Other family medicine in Boynton Beach

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →